AECOM Q3 revenue beats on design business growth
Reuters2026/08/10 20:44
Overview
US infrastructure services firm's fiscal Q3 revenue beat analyst expectations
Company backlog rose 13% to a record high, driven by strong new wins
Outlook
AECOM now expects fiscal 2026 adjusted EPS of $3.95-$4.15 and adjusted EBITDA of $935-$965 mln
Company sees fiscal 2026 total NSR of $7.30-$7.35 bln and free cash flow of about $300 mln
Result Drivers
PROJECT CHARGE - $337 mln pre-tax charge from delayed Construction Management project drove quarterly loss; co cited lower subcontractor productivity as cause
DESIGN BUSINESS GROWTH - Net service revenue in design business rose 4% (5% adjusted for fewer working days), led by Americas and International segments
INTERNATIONAL SEGMENT IMPROVEMENT - International segment operating income rose 21% and margin increased 240 bps, helped by growth in UK and Australia and restructuring actions
Company press release: ID:nBw1ngjTza
Key Details
Metric |
Beat/Miss |
Actual |
Consensus Estimate |
Q3 Revenue |
Beat |
$3.59 bln |
$2.02 bln (7 Analysts) |
Q3 Loss Per Share |
|
$0.67 |
|
Q3 Operating Income |
|
-$75.98 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the construction engineering peer group is "buy"
Wall Street's median 12-month price target for AECOM is $100.50, about 32.5% above its August 7 closing price of $75.84
The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 13 three months ago
Reuters Recommended Reads
Aug 10 - Bernhard Capital to take Bowman Consulting private in $1 billion deal
Aug 10 - Business process solutions firm Conduent Q2 revenue slips
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bitcoin Presents Both Danger and Opportunity! ETFs Are Strengthening, But This Data Is Alarming!
XRP Traders Target $1.90 as On-Chain Ledger Value Expands 43 Times to $4.26 Billion

Following Novartis, Novo Nordisk (NVO.US) terminates two cardiovascular clinical trials.
Novo Nordisk (NVO.US) has terminated two additional clinical trials of its experimental cardiovascular drug.

Saudi Oil facilities hit in fresh strikes, WTI surges above $90